GOODMAN COREY S 4
4 · ALX ONCOLOGY HOLDINGS INC · Filed Feb 4, 2026
Research Summary
AI-generated summary of this filing
ALX Oncology (ALXO) 10% Owner Corey S. Goodman Buys 3.18M Shares
What Happened
Corey S. Goodman, reported as a 10% owner of ALX Oncology (ALXO), made a purchase of 3,184,713 shares on Feb 2, 2026 at $1.57 per share, for a total reported purchase value of $4,999,999. This filing (Form 4) reports a straight purchase (transaction code P), which is a direct buy of company stock rather than a sale or option exercise.
Key Details
- Transaction date: 2026-02-02; Filing date: 2026-02-04 (timely filing).
- Price and amount: 3,184,713 shares at $1.57 each; total = $4,999,999.
- Transaction type: P = Purchase (open market or private purchase).
- Shares owned after transaction: Not specified in the provided filing excerpt.
- Footnotes of note:
- Several blocks of shares are held of record by venBio entities (venBio Global Strategic Fund II, venBio Global Strategic Fund, venBio SPV, LLC) and other entities (Goodman Barinaga Trust; Emaldi Corporation). Goodman is a director/trustee/manager for these entities and disclaims direct beneficial ownership except for indirect pecuniary interests (see F1–F5).
- No derivative transactions, awards, gifts, or tax-withholding reported in this filing.
Context
This is a purchase by a reported 10% owner and affiliated institutional entities (venBio-related funds and related vehicles), not an ordinary executive salary sale. Purchases by insiders or large holders can be viewed as a positive signal of conviction, but filings do not state the buyer’s motivation. The filing is straightforward and timely; there’s no indication of option exercises, sales, or 10b5-1 plans in this report.
Insider Transaction Report
- Purchase
Common Stock
[F1]2026-02-02$1.57/sh+3,184,713$4,999,999→ 8,453,038 total(indirect: See footnote)
- 3,969,789(indirect: See footnote)
Common Stock
[F2] - 461,811(indirect: See footnote)
Common Stock
[F3] - 113,287(indirect: See footnote)
Common Stock
[F4] - 54,083(indirect: See footnote)
Common Stock
[F5]
Footnotes (5)
- [F1]The shares are held of record by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. The reporting person, a director of venBio Global Strategic GP II, Ltd., disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest therein.
- [F2]The shares are held of record by venBio Global Strategic Fund, L.P. venBio Global Strategic GP, L.P. is the general partner of venBio Global Strategic Fund, L.P. and venBio Global Strategic GP, Ltd. is the general partner of venBio Global Strategic GP, L.P. The reporting person, a director of venBio Global Strategic GP, Ltd., disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest therein.
- [F3]The shares are held of record by venBio SPV, LLC, which is wholly-owned by venBio Global Strategic Fund, L.P. The reporting person, a managing director of venBio SPV, LLC, disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest therein.
- [F4]The shares are held of record by the Goodman Barinaga Trust for which the reporting person serves as trustee.
- [F5]The shares are held of record by Emaldi Corporation for which the reporting person serves as a director. The reporting person disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest therein.